# Round 2 — Adversarial Rebuttal — openai/gpt-6-astra-pro

*This reviewer is **Reviewer A** in the anonymised dossier. It was shown all six round-1 reviews and asked to concede, withdraw, rebut, and re-rank. Generated 2026-09-05 07:07 PDT via OpenRouter. Tokens: 60228 in / 8391 out. 251s.*

---

**1. CONCEDED — where another reviewer beat me.**

- **Reviewer B: the shared-K174 argument is stronger than I made explicit.** I noted that K174 in the T36 clone undermines sufficiency. B identifies the more direct implication: **if that clone was the swap recipient, donor and recipient both encoded K174, so the observed swap gain cannot be attributed to a K↔R change at position 174.** That separates evidence for the substituted region from evidence for the proposed residue. The stock-identity qualification remains essential; B sometimes drops it too readily.

- **Reviewer G: exploratory planning and mechanistic validation require different evidential thresholds.** My verdict insufficiently distinguished rejecting the **specified K174R-centred design rationale** from stopping all exploratory design. A statistically supported, background-specific substitution effect can justify further investigation without establishing necessity, sufficiency, or a containment mechanism. G wins that decision-theoretic distinction—not the claim that the reciprocal substitution is uniquely decisive, nor the specific expanded construct programme.

**2. WITHDRAWN — my own claims that do not survive.**

> “Do not proceed to the proposed construct design now … resolve experimental-unit, stock-provenance, source-availability, and primary-source uncertainties before committing to that design.”

**I weaken the implied all-or-nothing sequencing requirement.** These uncertainties invalidate confident commitment to the stated mechanistic rationale; they do not establish that every uncertainty must be resolved before any exploratory planning. Primary-source retrieval and provenance checks can also proceed alongside planning. My rejection of the specified programme as an evidence-backed containment strategy survives.

> “The most informative quantity is the transmission-specific effect size … after accounting for infectious-virus availability in the source plant.”

**I withdraw its status as the uniquely most informative quantity and qualify “transmission-specific.”** Source availability may be a **mediator of the substitution’s effect**, not merely a confound. Adjusting for a post-substitution mediator changes the causal question and can introduce bias without additional assumptions. A difference mediated through source availability would weaken a direct vector-interface mechanism, but would not erase a causal contribution to transmission. My original wording risked treating those conclusions as interchangeable.

I retain my principal numerical findings: the Fisher result, baseline interval, percentage-point corrections, and approximately 38% recovery of the baseline-to-donor gap survive recalculation.

**3. REBUTTED — criticisms by others that are wrong.**

- **Reviewers E and F: the Fisher statistics are inaccurate; B is broadly right, and D/G agree with my result.** For the table
  \[
  \begin{pmatrix}
  16&74\\
  1&65
  \end{pmatrix},
  \]
  the conventional probability-ordered, two-sided Fisher test gives **\(p\approx0.00116\)**. The odds ratio is
  \[
  \frac{16\times65}{74\times1}=14.05.
  \]
  E’s **0.0002** is wrong for this test; F’s **0.0015** is not an accurate rounding. D/G’s **0.0012** is correct, and B’s **0.001–0.003** contains the answer. This establishes a count-level difference, conditional on valid experimental units—not its protein-level mechanism.

  For **1/66**, the equal-tailed Clopper–Pearson interval is approximately **0.038–8.16%**. D/G and my original review are correct; B/E/F perpetuate the brief’s incorrect **7.7%** upper endpoint. Different legitimate interval methods should not be conflated with errors: my Wilson interval, **0.27–8.10%**, answers a differently constructed interval question.

- **Reviewer B: “‘CPm adds <1%’ is descriptively true” is factually wrong. Reviewer G’s stronger CPm-null interpretation is statistically wrong.**
  \[
  17/90-16/90=1/90=1.111\text{ percentage points}.
  \]
  Even the rounded percentages give **18.9−17.8 = 1.1 points**, not less than one. G correctly obtains **Fisher \(p=1.00\)**, but incorrectly treats that as strong functional evidence excluding CPm. A large p-value does not establish equivalence; the approximate difference interval spans **−10 to +12.5 points**. Moreover, **CPm and the 5′-UTR changed together**. Their separate contributions are unidentified. G’s phrase “CPm coding variation is excluded” also overreaches amino-acid identity: synonymous coding variation remains possible.

- **Reviewer D: “nearly half the transmission determinant lies outside the 5′-end entirely” does not follow. Reviewer E’s “strongly suggests” version also overweights the subtraction.** The numerical residual is:
  \[
  100(95/215)-23=21.186\text{ points}.
  \]
  That is approximately **49.7%** of the **42.671-point** baseline-to-donor difference. It is **not a genomic allocation**. Cross-study conditions, uncertain construct boundaries, compatibility effects and interactions can all prevent a substitution from reproducing the donor phenotype. One cannot infer that half the causal contribution physically resides elsewhere.

- **Reviewers B, D, E, F and G variously overstate the residue falsification.** FS577 and T30 sharing R174 while differing in transmission disproves a simple **residue-alone prediction**, not every possible conditional effect of residue 174. Using the supplied counts:
  \[
  24.1/(100\times2/127)=15.3035.
  \]
  Thus the difference is approximately **15.3-fold**, not evidence that the residue has “zero predictive validity” in every relevant model, as D claims. Nor does this pair by itself establish both necessity and sufficiency claims about K174. Necessity also depends on what qualifies as “high” transmission; FS577 is explicitly labelled moderate.

  The defensible conclusion is **unsupported residue-level causality**, not demonstrated biological irrelevance. E additionally misreads the brief when saying its chain “correctly acknowledges” neither necessity nor sufficiency: the brief acknowledges insufficiency while continuing to claim correlation.

- **Reviewer F: overlapping T36/T30 intervals do not undermine their shared low-transmission classification.** Their rates are **1.515% and 1.575%**, with **Fisher \(p=1.00\)**. Failure to distinguish two low rates is entirely compatible with both being much lower than T68-1’s **44.186%**. Temporal stability is unestablished because longitudinal evidence is absent—not because these intervals overlap.

- **Reviewers B and D, and my original emphasis: source titre does not automatically distinguish a “transmission determinant” from a non-determinant.** B’s statement that disappearance after titre matching would make p33 “a fitness/movement gene, not a transmission determinant” imposes an unjustified definition. A gene can causally affect transmission through donor availability. What would weaken is the **direct vector-interaction interpretation**. D’s suggestion that normalizing by RNA copy number isolates virion–vector compatibility is likewise too strong: RNA abundance does not equal accessible infectious particles, and simple normalization need not identify a direct causal effect.

- **Reviewer G: reciprocal effects are not logically required for causality.** “Permissive rather than causal” is a false dichotomy. A permissive factor can be causal in one background, and epistasis can produce asymmetric substitution effects. The existing gain also does not establish G’s description of p33 as “necessary.” Calling one reciprocal comparison the “only experiment” capable of breaking the hypothesis is unsupported.

- **Reviewers G, B and E: several design-statistics claims need qualification.** G’s small-effect power calculation is substantially right: for independent groups with **90 observations each**, distinguishing **17.8% from 23.0%** has approximately **14% power** under a standard two-proportion approximation; about **940–950 per group** gives 80% power at two-sided \(\alpha=0.05\). But Harper’s denominator is unknown, so **14% is a hypothetical scenario, not the actual power of the published comparison**.

  G’s familywise calculation,
  \[
  1-0.95^7=30.17\%,
  \]
  is correct **for seven independent tests under the complete null**. Seven constructs do not automatically imply those seven tests, especially with shared controls. B’s blanket **30–50% power** similarly lacks specified baseline rates and contrasts. E’s assertion that its proposed pilot is feasible within three weeks has no scheduling evidence in the brief.

- **Reviewer D: a small denominator does not make comparison “statistically invalid.”** Missing denominators prevent the intended assessment; small known denominators produce imprecision and potentially low power. Those are different problems. Likewise, Harper’s percentage is inadequate for the proposed inferential subtraction, not literally devoid of all evidential information.

**4. SURVIVING FINDINGS — ranked.**

1. **JUDGEMENT — The evidence does not establish selective transmission containment with preserved viral function.**  
   A transmission-increasing regional substitution does not demonstrate that the proposed alterations will selectively disable transmission rather than impair infection, assembly or movement. Neither the residue-level mechanism nor preservation of the required functions is established. **Raised explicitly by A; related mechanistic concerns by B, D and G.**

2. **CHECKABLE — The brief contains no residue-specific causal evidence and leaves sequence–phenotype linkage unresolved.**  
   K174 is listed in both T68-1 and the T36 infectious clone; the field A174 entry is explicitly an artifact. The brief does not establish which accession represents each phenotyped stock. Conditional on clone identity, the successful substitution did not change K174. **Raised by A, B and E; residue-pattern objections also by D, F and G.**

3. **CHECKABLE — The evidence needed to assess experimental independence is absent.**  
   The brief labels denominators as aphids but does not establish whether they are independently attributable transmission events, pooled exposures, or clustered observations. Consequently, binomial intervals and Fisher tests are conditional calculations, not unconditional validation of the experiments. **Raised explicitly by A; missing replication noted by F.**

4. **CHECKABLE — The p61/p65 “residual” lacks a verified quantitative foundation.**  
   Harper’s **23%** has no denominator or verified construct boundaries in the brief; **p65?/p61?** remain question marks. The 2026 source supplies an abstract interpretation without inspectable construct-level results. **Raised by all six reviewers.**

5. **JUDGEMENT — Neither specific p61/p65 necessity nor a measured 5.2-point residual follows.**  
   The subtraction **23−17.8=5.2 points** is arithmetically legitimate but not an identified causal effect. Neither additional-gene attribution nor localization of the larger donor residual is justified. **Raised by all six reviewers; D/E overextended the localization argument.**

6. **CHECKABLE — “Most of the gap,” “16-fold,” and “CPm adds <1%” misstate the supplied numbers.**  
   From the counts:
   - Baseline-to-donor difference: **42.671 points**.
   - Substitution increase: **16.263 points**.
   - Fraction recovered: **38.1%**, not most.
   - T68-1/T36 ratio: **29.163-fold**, not 16-fold.
   - Combined CPm/UTR increment: **1.111 points**, not less than one.

   **Raised collectively by A, B, D, E and G; A correctly identified all three corrections.**

7. **JUDGEMENT — CPm involvement is not falsified.**  
   **240/240 amino-acid identity** excludes differences in that amino-acid sequence as the explanation for the particular comparison, assuming correct stock matching. It does not exclude expression, interactions or RNA-level effects. The bundled **16/90 versus 17/90** comparison establishes neither component-specific absence of effect nor equivalence. **Raised by all six, although B/D/G sometimes exceeded this narrow conclusion.**

8. **CHECKABLE — FS577 lacks the denominator and assay information needed to assess its quantitative anchor role.**  
   **24.1%** alone does not specify sampling uncertainty or establish comparability with the other assays. This weakens both the CPm phenotype contrast and the residue association argument. **Raised by A, B, D, E and G.**

9. **JUDGEMENT — The substitution evidence is stronger than the proposed transmission mechanism.**  
   The count-level gain survives statistical scrutiny, but RNA/context effects, source availability and background dependence remain possible explanations; heterologous viroporin activity does not identify an aphid-transmission mechanism. **Raised by all six, with differing emphasis.**

**5. VERDICT AFTER REBUTTAL.**

My verdict remains **do not commit to the specified K174R-centred p33/p61/p65 programme as an evidence-backed containment strategy**, but G persuaded me to withdraw any blanket prohibition on exploratory planning, while B’s shared-K174 argument strengthened the rejection of the residue-specific rationale.
